Latest News & Features
Refine Search
Americas
Janssen Products, a subsidiary of Johnson & Johnson, has sued Indian pharmaceutical company Hetero Drugs for applying to market a generic version of its HIV treatment Prezista. 14 March 2013
article
Recent CJEU judgements on the interpretation of SPC regulations are not clear and have left judges frustrated, said Huw Evans, partner at Norton Rose LLP, at the 1st Annual Life Sciences Law Forum in London. 7 March 2013
Europe
Day two of the 1st Annual Life Sciences Forum in London saw panellists discuss the European Unitary Patent and the Unified Patent Court. 6 March 2013
Asia-Pacific
Law firm Maurice Blackburn revealed on Monday that it will appeal against an Australian court decision that backed Myriad Genetics’ ownership of a human gene mutation linked to breast cancer. 5 March 2013
Big Pharma
India’s patent authorities have dealt a blow to German pharma company Bayer by refusing to overturn an order forcing the company to license one of its patented drugs. 4 March 2013
Sectors
Oxitec’s pioneering insect sterilisation technique could eradicate dengue fever and malaria and cut crop damage worldwide. LSIPR spoke to CEO Hadyn Parry about the company’s development and its approach to protecting its inventions. 28 February 2013
Big Pharma
ViiV Healthcare, a public health joint venture between GlaxoSmithKline, Shionogi and Pfizer, has signed up to the Medicines Patent Pool (MPP) to provide greater access to affordable AIDS treatments in developing countries. 28 February 2013
Americas
The US Food and Drug Administration has approved two generic versions of Reckitt Benckiser’s heroin replacement tablet Suboxone – despite Reckitt’s claims that the product is unsafe. 26 February 2013
Europe
The UK government announced a change to the Patent Act on Tuesday that will allow parties to run drug trials without infringing other parties’ patents. 26 February 2013
Big Pharma
England’s Court of Appeal has affirmed a 2012 High Court ruling that pharmaceutical company Genentech’s patent covering human vascular endothelial growth factor antagonists is valid and has been infringed by Regeneron and Bayer Pharmaceutical’s drug Eylea. 25 February 2013